Immunome announces $200 million stock offering By Investing.com
[ad_1]
© Reuters.
BOTHELL, Wash. – Immunome, Inc. (NASDAQ:IMNM), a biotechnology firm focusing on cancer therapies, has unveiled plans for a public offering of $200 million in common stock. The company intends to grant underwriters a 30-day option to buy up to an additional 15% of shares sold in the offering. The completion, timing, and terms of the offering are not guaranteed.
J.P. Morgan, TD Cowen, Leerink Partners, and Guggenheim Securities are the joint book-running managers, with Wedbush PacGrow as the lead manager. The offering will be made under an effective shelf registration statement filed with the U.S. Securities and Exchange Commission (SEC) on February 13, 2024.
Immunome’s portfolio includes a range of modalities targeting cancer, such as antibody-drug conjugates (ADCs), radioligand therapies, immunotherapies, and small molecules. The company employs a proprietary technology to screen and characterize novel antibodies and targets rapidly.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
[ad_2]
Source link
© Reuters.
BOTHELL, Wash. – Immunome, Inc. (NASDAQ:IMNM), a biotechnology firm focusing on cancer therapies, has unveiled plans for a public offering of $200 million in common stock. The company intends to grant underwriters a 30-day option to buy up to an additional 15% of shares sold in the offering. The completion, timing, and terms of the offering are not guaranteed.
J.P. Morgan, TD Cowen, Leerink Partners, and Guggenheim Securities are the joint book-running managers, with Wedbush PacGrow as the lead manager. The offering will be made under an effective shelf registration statement filed with the U.S. Securities and Exchange Commission (SEC) on February 13, 2024.
Immunome’s portfolio includes a range of modalities targeting cancer, such as antibody-drug conjugates (ADCs), radioligand therapies, immunotherapies, and small molecules. The company employs a proprietary technology to screen and characterize novel antibodies and targets rapidly.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
About The Author
